June 16, 2023 06:33 AM EDTUpdated June 20, 05:55 PM

FDA approves Roche’s second CD20xCD3 bispecific in certain lymphomas

Kyle LaHucik

Senior Reporter

The FDA granted accelerated approval to Genentech’s CD20xCD3 bispecific for patients with a certain type of non-Hodgkin’s lymphoma on Thursday night …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA approves Roche’s second CD20xCD3 bispecific in certain lymphomas

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

Gardasil demand in China sinks, and Merck expects the same next quarter

‘Imitation is best form of flattery’: Regeneron CEO comments on Amgen’s Eylea biosimilar

Amgen makes pipeline cuts, but obesity plans remain the focus

UCB's anti-tau Alzheimer's program fails Phase 2 primary endpoint, but highlights positive secondaries

AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65M

Q&A: Jade CEO talks about reverse merger and IgAN drugs

FDA ap­proves Roche’s sec­ond CD20xCD3 bis­pe­cif­ic in cer­tain lym­phomas

Senior Reporter

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

FDA approves Roche’s second CD20xCD3 bispecific in certain lymphomas